Clicky

Soleno Therapeutics, Inc.(SLNO) News

Date Title
Oct 9 SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
Oct 8 Why Soleno Therapeutics Stock Blasted 9% Higher Today
Oct 8 Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
Oct 3 Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc
Oct 2 High Growth Tech Stocks To Watch In The United States
Sep 16 Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Aug 28 Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
Aug 28 Soleno wins FDA priority review for Prader-Willi therapy
Aug 28 Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
Aug 27 Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Aug 7 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Jul 29 When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)?
May 15 Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
May 9 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 8 While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
May 3 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
May 2 Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Apr 30 Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Apr 29 Why Soleno Therapeutics Stock Is Skyrocketing Today
Apr 29 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)